Standard BioTools (LAB) UBS Global Healthcare Conference 2024 summary

Strategic vision and company evolution

• Mission to build a next-generation life science company by integrating advanced technologies through M&A, leveraging experience from Danaher and strong investor backing.

• Assembled a portfolio including Fluidigm and SomaLogic, focusing on multi-omics products for long-term growth, targeting $170M-$175M revenue in 2024 and aiming for profitability by 2026.

• Emphasis on disciplined operations, Lean principles, and addressing scaling challenges such as quality, manufacturing, and sales force development.

Operational improvements and product portfolio

• Improved on-time delivery from 78% to 98% and reduced downtime on key instruments, enhancing customer satisfaction and inventory management.

• Rationalized product lines, consolidating to robust, margin-accretive instruments like Biomark X9, eliminating legacy products and technical debt.

• Biomark business turned from a $25M loss to break-even on a contribution basis, with future growth expected.

Q3 performance and market environment

• Achieved solid execution and improved revenue predictability, with strong growth in SomaScan Assay Services and consumables (13% YoY growth).

• Facing tough comps due to large pharma projects in 2023, with 2024 seeing a challenging macro environment and constrained CapEx, especially in Europe and Asia.

• New sales leadership in APAC and EMEA, maintaining a bullish long-term outlook despite current headwinds.